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Abstracts / Osteoarthritis and Cartilage 21 (2013) S63–S312 S267relationship between NFlB activity and mechanical allodynia was
observed with a Spearman r of -0.69 (p < 0.0001) (Fig. 1e). NF-lB
activity was moderately correlated to weight distribution with
a Spearman r of -0.39 (p ¼ 0.0002).
Conclusions: This study demonstrates the use of non-invasive lumi-
nescence in vivo imaging tomeasure NF-lB activity in amousemodel of
osteoarthritis and the comparison of a key molecular event in arthritis
to pain sensitivity development. MIA injection induced a transient
increase in NF-lB activity at early time points in the intra-articular joint
that was correlated with developing pain sensitivities in this model of
arthritis. The demonstrated relationship between NFlB activity,
mechanical allodynia, and weight bearing suggests the use of NFlB
luminescence imaging as a novel imaging biomarker of joint dysfunc-
tion in this model.
Acknowledgments: NIH AR047442, NIH AR050245
Ă(p<0.05 compared to preop (#) and sham (*))
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A PHASE 3 STUDY OF LOWER-DOSE DICLOFENAC SUBMICRON
PARTICLE CAPSULES DEMONSTRATES EFFECTIVE PAIN RELIEF IN
PATIENTS WITH OSTEOARTHRITIS
A. Gibofsky y, M. Hochberg z, C. Young x. yHosp. for Special Surgery, New
York, NY, USA; zUniv. of Maryland, Baltimore, MD, USA; x Iroko
Pharmaceuticals, LLC, Philadelphia, PA, USA
Purpose: Non-steroidal anti-inﬂammatory drugs (NSAIDs) are
commonly prescribed for managing osteoarthritis (OA) pain; however,
their use is limited by potentially serious dose-related gastrointestinal,
cardiovascular, and renal adverse events (AEs). AUnited States Food and
Drug Administration Public Health Advisory recommended that NSAIDs
be administered at the lowest effective dose for the shortest duration.
Investigational submicron NSAIDs are being developed using proprie-
tary SoluMatrix technology that could provide effective pain relief at
lower doses than currently available oral prescription NSAIDs. Diclofe-
nac submicron particle capsules previously demonstrated analgesia in
a post-surgical model of mild to moderate pain. This Phase 3 study
evaluated diclofenac submicron particle capsules in patients with OA
pain.
Methods: This randomized, multi-center, double-blind, parallel-group
study enrolled 305 patients 41-90 years of age with OA of the hip or
knee. Patients had Kellgren-Lawrence grade II-III radiographic OA
severity, were chronic NSAID or acetaminophen users, with baseline
WOMAC pain subscores 50mm, that increased by 15mm following
NSAID discontinuation. Patients were randomized to diclofenac
submicron particle capsules 35mg TID or 35mg BID, or placebo. The
primary endpoint was mean change from baseline in WOMAC pain
score at week 12.Results: Most patients were women (203 [66.6%]) and Caucasian (245
[80.3%]) with a mean age of 61.6 (8.9) years. Diclofenac submicron
particle capsules 35mg TID demonstrated signiﬁcant pain improvement
(-44.1; P¼0.0024; Figure) compared with placebo (-32.5) at week 12.
There was numerical evidence of pain improvement for diclofenac
submicron particle capsules 35mg BID at week 12, although this did not
achieve statistical signiﬁcance (-39.0; 95% conﬁdence interval [CI], -33.3
to -44.8; P¼0.0795). Patients receiving diclofenac submicron particle
capsules 35mg TID (-37.4; 95%CI, -31.7 to -43.1; P<0.001) and diclofenac
submicron particle capsules 35mg BID (-31.4; 95%CI, -26.0 to -36.8;
P¼0.0052) experienced improvements in WOMAC pain subscale scores
at weeks 2, compared with placebo (-21.6; 95%CI, -27.1 to -16.1). At
week 6, patients administered diclofenac submicron particle capsules
35mg TID (-43.5; 95%CI, -37.5 to -49.5; P¼0.0011) maintained clinical
improvements in WOMAC pain subscale scores compared with placebo
(-31.1; 95%CI, -25.3 to -36.8). The average improvement in totalWOMAC
pain subscale scores favored diclofenac submicron particle capsules
35mg TID (-35.9; P¼0.0002) and 35mg BID (-30.3; P¼0.0363) compared
with placebo (-23.2). A higher proportion of patients who received
diclofenac submicron particle capsules 35mg TID (26.0%, 25/98) or BID
(22.5%, 23/104) reported their pain as “very much improved” compared
with placebo (6.3%, 6/103). The most frequent treatment-emergent AEs
were similar across treatment groups and included diarrhea, headache,
nausea, and upper respiratory tract infection.
ĂConclusions: Investigational lower-dose, diclofenac submicron particle
capsules provided better overall relief from OA pain compared with
placebo and were generally well-tolerated. These results suggest that
diclofenac submicron particle capsules are a potentially promising
therapeutic option for patients with OA pain.
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LOWER-DOSE INDOMETHACIN SUBMICRON PARTICLE CAPSULES
PROVIDE EFFECTIVE ACUTE PAIN RELIEF: PHASE 3 STUDY RESULTS
R. Altman y, K. Saag z, S. Daniels x, C. Young k. yUniv. of California, Los
Angeles, David Geffen Sch. of Med., Los Angeles, CA, USA; zUniv. of
Alabama at Birmingham, Birmingham, AL, USA; x Premier Res. Group
Limited, Clinical Res. Ctr.s, Philadelphia, PA, USA; k Iroko
Pharmaceuticals, LLC, Philadelphia, PA, USA
Purpose: Although often prescribed for treatment of acute pain, NSAIDs
have the potential for the development of dose-related gastrointestinal,
cardiovascular, and renal complications. A United States Food and Drug
Administration Public Health Advisory recommended that NSAIDs
should be administered at the lowest effective dose for the shortest
duration consistent with individual patient treatment goals. Investiga-
tional submicron NSAIDs are being developed using proprietary Sol-
uMatrix technology that could provide effective pain relief at lower
doses than currently available oral NSAIDs. In a Phase 2 study, indo-
methacin submicron particle capsules provided good pain relief and
were generally well-tolerated in a post-surgical model of mild to
moderate pain. This study evaluated the analgesic efﬁcacy and safety of
lower-dose, indomethacin submicron particle capsules and celecoxib
versus placebo in a validated post-surgical model of moderate to severe
pain.
Methods: This multi-center, double-blind study enrolled patients 18-68
years of age who underwent a primary, unilateral ﬁrst metatarsal
Abstracts / Osteoarthritis and Cartilage 21 (2013) S63–S312S268bunionectomy with osteotomy and ﬁxation under regional anesthesia.
Patients with a pain intensity rating of 40mm on a 100mm Visual
Analog Scale (VAS) were randomized to receive indomethacin submi-
cron particle capsules (40mg TID or BID or 20mg TID), celecoxib (400mg
loading dose; 200mg BID), or placebo. The primary endpoint was the
summed pain intensity difference measured by VAS over 48 hrs (VAS
SPID-48).
Results: Of the 462 patients enrolled, most (83.1%) were women with
a mean age of 41.2 (12.5) years. Indomethacin submicron particle
capsules 40mg TID (509.691.9), 40mg BID (328.092.9), and 20mg TID
(380.592.9) reduced pain (VAS SPID-48; P0.046 for all 3 groups)
compared with placebo (67.891.4; Figure). Although there was some
evidence of analgesia for celecoxib (279.491.9) VAS SPID-48 did not
achieve statistical signiﬁcance compared with placebo. Indomethacin
submicron particle capsules 40mg TID (30.7; P¼0.013) and 40mg BID
(29.8; P¼0.014) achieved better pain control over 4 hrs after study entry
(VAS SPID-4) compared to placebo (8.9). Similarly, indomethacin
submicron particle capsules 40mg TID (2.5; P¼0.003) and 40mg BID
(2.1; P¼0.022) provided greater total pain relief over 4 hrs after study
entry (TOTPAR-4) compared with placebo (1.2). Some evidence of pain
control was observed as early as 30 min (VAS SPID) in the indomethacin
submicron particle capsules 40mg TID (2.9) and 40mg BID (2.6) groups
compared with placebo (0.2). AEs were generally similar across treat-
ment groups and included nausea, localized post-procedural edema,
dizziness, and headache.
ĂConclusions: In this study, investigational lower-dose, indomethacin
submicron particle capsules provided effective pain control compared
with placebo in a post-surgical model of moderate to severe acute pain.
Indomethacin submicron particle capsules are a potentially promising
option for patients with acute pain.
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ACUTE AND SHORT-TERM EFFECTS OF INTRA-ARTICULAR KNEE PAIN
RELIEF ON PAIN SENSITIZATION IN KNEE OA: A COHORT STUDY
T. Joergensen y, T. Graven-Nielsen z, S. Rosager y, L. Klokker y,
K. Ellegaard y, B. Danneskiold-Samsoee y, H. Bliddal y, M.
Henriksen y. y The Parker Inst., Dept. of Rheumatology, Copenhagen Univ.Table 1
Test day Day -8 Day 0
Test 1 Test 2
Mean SE Mean
Current knee pain, cm (0-10) 3.0 0.3 2.8
Hand-held algometer, kPa
Corpus Hoffa medial 558.1 23.8 582.1
Corpus Hoffa lateral 611.2 25.3 656.5
Lateral joint line 490.6 17.3 524.6
Quadriceps tendon, lateral 507.6 23.5 527.9
Quadriceps tendon, median 580.2 22.9 597.1
Quadriceps tendon, medial 490.4 21.3 538.3
Medial joint line 506.1 23.3 513.5
Centre of patella 629.0 23.7 669.5
Extensor carpi radialis (control point) 412.0 16.1 430.5Hosp., Frederiksberg, Denmark; zCtr. for Sensory-Motor Interaction,
Dept. of Hlth.Sci. and Technology, Faculty of Med., Aalborg Univ.,
Aalborg, Denmark
Purpose: Pain is the cardinal symptom of knee osteoarthritis (OA).
Recently hyperalgesia and widespread pain was shown in knee OA
patients, as both the knee and surrounding sites were hypersensitive
to pressure pain testing compared with controls. Hyperalgesia and
spontaneous pain in knee OA is most likely related to increased
sensitivity of nociceptors located in deep tissue (peripheral sensitisa-
tion) and/or by increased responses in dorsal horn or supraspinal
neurons (central sensitisation). However, the effects of pain relief on
pain sensitivity in knee OA are unknown. The purpose of this study
was to assess the effects of intra-articular pain relief and anti-
inﬂammation on pain sensitivity in the knee and surrounding tissues
in knee OA patients.
Methods: Twenty-ﬁve consecutive knee OA patients with symptomatic
knee OA according to the ACR criteria were included in this observa-
tional study, with tests of pressure pain thresholds (PPT) before and
after treatment of the knee with intra-articular injection of 40 ml
glucocorticoid (depomedrol 40 mg/ml) and 10 ml lidocaine (10%). The
patients rated their current pain continuously on a visual analogue scale
(VAS), with 0 indicating “no pain” and 10 deﬁned “maximum pain”.
Hand-held, computer-controlled and cuff pressure algometers were
used to assess PPT in the peripatellar region, on vastus lateralis, on
tibialis anterior and the extensor carpi radialis longus muscles (control
site). The PPTs were assessed on day -8 and day 0 before, immediately
after the injection (day 0) and two weeks after the injection (day 14).
Results: The current knee painwas signiﬁcantly lower (see table 1) after
treatment, indicating clinical efﬁcacy of the injection. We found
reduced pain sensitivity (higher PPT levels) following intra-articular
lidocaine (see table 1 and 2 at day 0 - post lidocaine) in both the knee
and in the surrounding muscles, whereas the control assessment site
was not affected by either treatments. There was a trend towards even
greater reduction in pain sensitivity at day 14 after the intra-articular
treatment (see table 1 and 2 at day 14 follow-up) in both the knee and in
the surrounding muscles.
Conclusions: This study shows that intra-articular knee pain relief
leads to reduced pain sensitivity in the knee and surrounding muscles
as well. This effect may be more pronounced after a combination of
anaesthetic action and reduction of inﬂammation. Deeper under-
standing of the underlying mechanisms may inﬂuence the choice of
treatment in the future to avoid or prevent hypersensitivity in knee OA
patients.
Acknowledgments: This study was supported by grants from The Oak
Foundation, Center for Sensory-Motor Interaction (SMI) at Aalborg
University and The Danish Agency for Science Technology and Inno-
vation (FI).
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THE REDUCTION OF PAIN BY CHONDROCYTES SECRETING TGF-b1 IN
A RAT MONOSODIUM IODOACETATE (MIA)-INDUCED
OSTEOARTHRITIS MODEL
K.B. Choi, Sr., Hyeon Youl Lee, Dae-Wook Kim, Sujeong Kim. Kolon Life
Sci., Seoul, Republic of KoreaDay 14 P for trend
Post lidocaine Follow-up(post
steroid)
SE Mean SE Mean SE
0.3 1.8 0.3 1.3 0.3 0.0001
23.8 659.6 23.8 689.3 24.2 0.0001
25.3 689.8 25.3 722.9 25.8 0.0057
17.3 601.3 17.3 573.8 17.6 <.0001
23.6 636.8 23.6 560.9 23.9 <.0001
22.9 675.3 22.9 672.8 23.4 0.0011
21.3 625.3 21.3 582.9 21.8 <.0001
23.3 596.5 23.3 568.3 23.6 0.0006
23.7 707.3 23.7 702.3 24.1 0.0341
16.1 452.5 16.1 428.7 16.5 0.3013
